Skip to main navigation Skip to search Skip to main content

Proceedings of the inaugural symposium on dengue human challenge studies “Challenging the norm: Accelerating dengue countermeasures through human studies”

  • Shirin Kalimuddin
  • , Adam T. Waickman
  • , Panisadee Avirutnan
  • , Mohammad Shafiul Alam
  • , Christopher Chiu
  • , Barnaby E. Young
  • , Christopher W. Woods
  • , Petra C. Fay
  • , Sheila K. Pakir
  • , Jo Anne Manski-Nankervis
  • , Claus Bolte
  • , Andrew Pengilley
  • , Marco Cavaleri
  • , John C.W. Lim
  • , Stephen J. Thomas
  • , Albert I. Ko
  • , Eng Eong Ooi
  • Singapore General Hospital
  • Duke-NUS Medical School
  • SUNY Upstate Medical University
  • Bangladesh (Icddr,b)
  • Imperial College London
  • National Centre for Infectious Diseases
  • Tan Tock Seng Hospital
  • Lee Kong Chian School of Medicine
  • Duke University
  • Wellcome Trust
  • Kaye Consulting
  • National Healthcare Group Polyclinics, Singapore
  • University Hospital Basel and University of Basel
  • Therapeutic Goods Administration
  • European Medicines Agency
  • Yale University
  • Fundacao Oswaldo Cruz
  • SingHealth Duke-NUS Academic Medical Centre
  • NUS

Research output: Contribution to journalArticlepeer-review

Abstract

On 12th June 2025, Duke-NUS Medical School, supported by the Global Dengue and Aedes-Transmitted Diseases Consortium (GDAC), hosted a one-day symposium in Singapore titled “Challenging the norm: Accelerating dengue countermeasures through human challenge studies”. Comprising sessions on both dengue and other viral infection models, the symposium explored how human challenge studies could address gaps in dengue pathogenesis and immunity to inform vaccine development and application. Keynote speakers highlighted persistent challenges in dengue vaccine development, including incomplete protection across all four dengue viruses, complexities in dengue immunity, and past safety concerns that have influenced regulatory pathways. Case studies from Thailand and Bangladesh illustrated the feasibility and safety of dengue challenge studies in endemic settings. Parallel discussions drew lessons from human infection models of SARS-CoV-2 and other respiratory viruses that are directly relevant to expanding the use of dengue human challenge studies. Sessions on public engagement and regulatory frameworks emphasised the importance of trust, transparent communication, and harmonisation in the design, conduct, and acceptance of challenge studies. Overall, the symposium highlighted that human challenge studies, if implemented thoughtfully, can advance dengue vaccine research, accelerate clinical evaluation and regulatory approval of vaccine candidates, and support evidence-based public health strategies to strengthen global dengue control efforts.

Original languageEnglish
Article numbere0013889
JournalPLoS Neglected Tropical Diseases
Volume20
Issue number1
DOIs
Publication statusPublished - Jan 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being
  2. SDG 16 - Peace, Justice and Strong Institutions
    SDG 16 Peace, Justice and Strong Institutions

Fingerprint

Dive into the research topics of 'Proceedings of the inaugural symposium on dengue human challenge studies “Challenging the norm: Accelerating dengue countermeasures through human studies”'. Together they form a unique fingerprint.

Cite this